Telaprevir: all 67 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1CompletedNCT01994486Phase 2Results posted
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)TerminatedNCT01821963Phase 3Results posted
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedNCT01753557Phase 3Results posted
- Viral Kinetics in HCV Clearance in Subjects With HemophiliaCompletedNCT01704521Phase 1Results posted
- An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusTerminatedNCT01701063Phase 1/2Results posted
- Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant RecipientsTerminatedNCT01592006Phase 4Results posted
- Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3Results posted
- Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01492426Phase 3Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedNCT01468584Phase 3Results posted
- An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
- Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedNCT01466192Phase 3Results posted
- Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
- VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT01241760Phase 3Results posted
- VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir PlaceboCompletedNCT01054573Phase 3Results posted
- Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)CompletedNCT00892697Phase 2Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedNCT00781274Phase 3Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedNCT00780910Phase 3Results posted
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedNCT00780416Phase 3Results posted
- A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
- A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard TreatmentCompletedNCT00703118Phase 3Results posted
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedNCT00630058Phase 1Results posted
- A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)CompletedNCT00627926Phase 3Results posted
- Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CCompletedNCT00621296Phase 2Results posted
- Safety and PK Study of MP-424 to Treat Chronic Hepatitis CCompletedNCT00591214Phase 1Results posted
- An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT00580801Phase 2Results posted
- A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C InfectionCompletedNCT00561015Phase 2Results posted
- A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to TherapyCompletedNCT00535847Phase 2Results posted
- A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)CompletedNCT00420784Phase 2Results posted
- Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CCompletedNCT00372385Phase 2Results posted
- Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis CCompletedNCT00336479Phase 2Results posted
- Comparative Effectiveness and Tolerability of Boceprevir vs TelaprevirCompletedNCT02113631Not applicable
- Telaprevir in Genotype 3 HCVCompletedNCT02087111Phase 4
- Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)CompletedNCT02006745Phase 3
- Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus InfectionStatus unknownNCT01872936Phase 2
- Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnNCT01858961Phase 3
- Interaction Between Paroxetine and TelaprevirTerminatedNCT01841502Phase 2
- Pharmacokinetic Interactions Between Telaprevir and Un-boosted AtazanavirCompletedNCT01818856Phase 1
- A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and OmeprazoleCompletedNCT01786382Phase 1
- Clinical Pharmacology Study of MP-424CompletedNCT01766167Phase 1
- Hepatitis C Virus Post-Exposure Prophylaxis for Health Care WorkersWithdrawnNCT01766115Phase 4
- Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCompletedNCT01718158Phase 3
- Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedNCT01657552Phase 1
- Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy SubjectsCompletedNCT01646489Phase 1
- A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and TelaprevirCompletedNCT01635829Phase 1
- A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic ImpairmentCompletedNCT01600976Phase 1
- Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy SubjectsCompletedNCT01597895Phase 1
- VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
- An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver TransplantationCompletedNCT01571583Phase 3
- A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).CompletedNCT01563328Phase 1
- A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
- An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)CompletedNCT01513941Phase 3
- Telaprevir Open-Label Study in Co-Infected PatientsCompletedNCT01500616Phase 3
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC PolymorphismWithdrawnNCT01415141Phase 4
- TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.CompletedNCT01336829Phase 1
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
- Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
- Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy SubjectsCompletedNCT00958152Phase 1
- VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and EscitalopramCompletedNCT00933894Phase 1
- A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-StateCompletedNCT00933283Phase 1
- VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.CompletedNCT00903773Phase 1
- VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1
- Study of Telaprevir in Subjects With Hepatic ImpairmentCompletedNCT00509210Phase 1
- Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis CCompletedNCT00262483Phase 2
- VX-950 and Peginterferon for Hepatitis CCompletedNCT00251199Phase 1